1. Home
  2. VCIG vs LIXT Comparison

VCIG vs LIXT Comparison

Compare VCIG & LIXT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • VCIG
  • LIXT
  • Stock Information
  • Founded
  • VCIG 2013
  • LIXT 2005
  • Country
  • VCIG Malaysia
  • LIXT United States
  • Employees
  • VCIG N/A
  • LIXT N/A
  • Industry
  • VCIG Diversified Commercial Services
  • LIXT Biotechnology: Pharmaceutical Preparations
  • Sector
  • VCIG Consumer Discretionary
  • LIXT Health Care
  • Exchange
  • VCIG Nasdaq
  • LIXT Nasdaq
  • Market Cap
  • VCIG 22.5M
  • LIXT 20.5M
  • IPO Year
  • VCIG 2023
  • LIXT N/A
  • Fundamental
  • Price
  • VCIG $2.55
  • LIXT $4.52
  • Analyst Decision
  • VCIG
  • LIXT
  • Analyst Count
  • VCIG 0
  • LIXT 0
  • Target Price
  • VCIG N/A
  • LIXT N/A
  • AVG Volume (30 Days)
  • VCIG 654.9K
  • LIXT 152.0K
  • Earning Date
  • VCIG 10-06-2025
  • LIXT 11-11-2025
  • Dividend Yield
  • VCIG N/A
  • LIXT N/A
  • EPS Growth
  • VCIG N/A
  • LIXT N/A
  • EPS
  • VCIG 270.67
  • LIXT N/A
  • Revenue
  • VCIG $32,903,041.00
  • LIXT N/A
  • Revenue This Year
  • VCIG N/A
  • LIXT N/A
  • Revenue Next Year
  • VCIG N/A
  • LIXT N/A
  • P/E Ratio
  • VCIG $0.01
  • LIXT N/A
  • Revenue Growth
  • VCIG 24.77
  • LIXT N/A
  • 52 Week Low
  • VCIG $2.54
  • LIXT $0.64
  • 52 Week High
  • VCIG $4,644.00
  • LIXT $6.26
  • Technical
  • Relative Strength Index (RSI)
  • VCIG 34.69
  • LIXT 46.97
  • Support Level
  • VCIG $3.10
  • LIXT $3.91
  • Resistance Level
  • VCIG $4.60
  • LIXT $4.68
  • Average True Range (ATR)
  • VCIG 0.66
  • LIXT 0.46
  • MACD
  • VCIG -0.49
  • LIXT -0.09
  • Stochastic Oscillator
  • VCIG 0.00
  • LIXT 37.65

About VCIG VCI Global Limited

VCI Global Ltd is a holding company. The principal activities of the Company and its subsidiaries are the provision of business Strategy consultancy and technology development. The firm organized its consulting services into three main segments: Business Strategy Consultancy; Technology development, solutions and consultancy; and Others. It derives the majority of its revenue from the Business Strategy Consultancy segment, which focuses on listing solutions, investor relations, and boardroom strategies consultancy.

About LIXT Lixte Biotechnology Holdings Inc.

Lixte Biotechnology Holdings Inc is a biopharmaceutical company dedicated to improving patients' lives by developing a drug class called Protein Phosphatase 2A inhibitors. Its product pipeline is focused on inhibitors of protein phosphatase 2A, used in combination with cytotoxic agents and/or x-rays, immune checkpoint blockers, and other cancer therapies. The Company believes that inhibitors of protein phosphatases have therapeutic potential for a broad range of cancers. It focuses on the clinical development of a specific protein phosphatase inhibitor, referred to as LB-100, which has been shown to have clinical anti-cancer activity at doses that produce little or no toxicity.

Share on Social Networks: